| abstract |
Claim 1: A liquid formulation of a combination of insulin and long-acting insulinotropic peptide, characterized in that it comprises insulin and insulinotropic peptide, which are physiologically active peptides, and albumin-free stabilizer, wherein the stabilizer comprises a buffer solution, an alcohol of sugar, a non-ionic surfactant, and an isotonic agent. Claim 5: The liquid formulation according to claim 1, characterized in that the insulinotropic peptide is selected from the group consisting of glucagon-like peptide (GLP-1), glucagon-like peptide 2 (GLP-2), exendin-3 , exendina-4, and the precursors, agonists, derivatives, fragments and variants thereof, and a combination thereof. Claim 29: The liquid formulation according to claim 1, characterized in that it further comprises methionine. |